Enzo Biochem (NYSE:ENZ) Stock Passes Above Two Hundred Day Moving Average of $1.84

Enzo Biochem, Inc. (NYSE:ENZ – Get Rating)’s stock price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.84 and traded as high as $2.40. Enzo Biochem shares last traded at $2.29, with a volume of 82,638 shares trading hands.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on Enzo Biochem in a research note on Thursday, May 18th. They issued a “sell” rating for the company.

Enzo Biochem Price Performance

The stock has a market cap of $113.72 million, a P/E ratio of -3.18 and a beta of 1.04. The company has a debt-to-equity ratio of 0.01, a quick ratio of 0.64 and a current ratio of 1.13. The business has a 50 day simple moving average of $2.43 and a 200-day simple moving average of $1.84.

Enzo Biochem (NYSE:ENZ – Get Rating) last announced its quarterly earnings data on Monday, March 20th. The medical research company reported ($0.23) earnings per share (EPS) for the quarter. Enzo Biochem had a negative net margin of 43.44% and a negative return on equity of 67.73%. The business had revenue of $16.34 million during the quarter.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ENZ. Potomac Capital Management Inc. lifted its position in shares of Enzo Biochem by 37.2% during the 1st quarter. Potomac Capital Management Inc. now owns 780,509 shares of the medical research company’s stock valued at $1,897,000 after buying an additional 211,509 shares during the last quarter. Assenagon Asset Management S.A. purchased a new position in shares of Enzo Biochem during the 1st quarter valued at $185,000. Susquehanna International Group LLP lifted its position in shares of Enzo Biochem by 189.6% during the 4th quarter. Susquehanna International Group LLP now owns 28,228 shares of the medical research company’s stock valued at $40,000 after buying an additional 59,728 shares during the last quarter. Mirabella Financial Services LLP purchased a new position in shares of Enzo Biochem during the 1st quarter valued at $13,616,000. Finally, Virtu Financial LLC purchased a new position in shares of Enzo Biochem during the 2nd quarter valued at $62,000. Hedge funds and other institutional investors own 50.56% of the company’s stock.

Enzo Biochem Company Profile

(Get Rating)

Enzo Biochem, Inc is an integrated diagnostics, clinical lab, and life sciences company, which focuses on delivering and applying advanced technology capabilities to produce affordable reliable products and services that enable customers to meet their clinical needs. It operates through the following segments: Products, Clinical Services, and Therapeutics.